دورية أكاديمية
Promising new treatments for neovascular age-related macular degeneration.
| العنوان: | Promising new treatments for neovascular age-related macular degeneration. |
|---|---|
| المؤلفون: | Michels S; Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Währinger Gürtel 18-20, Allgemeines Krankenhaus 8i, 1090 Wien/Vienna, Austria. stephan.michels@meduniwien.ac.at, Schmidt-Erfurth U, Rosenfeld PJ |
| المصدر: | Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2006 Jul; Vol. 15 (7), pp. 779-93. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9434197 Publication Model: Print Cited Medium: Internet ISSN: 1744-7658 (Electronic) Linking ISSN: 13543784 NLM ISO Abbreviation: Expert Opin Investig Drugs Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Ashley Publications Ltd., c1994- |
| مواضيع طبية MeSH: | Angiogenesis Inhibitors/*therapeutic use , Drugs, Investigational/*therapeutic use , Macular Degeneration/*drug therapy , Neovascularization, Pathologic/*drug therapy , Vascular Endothelial Growth Factor A/*antagonists & inhibitors, Aging ; Angiogenesis Inhibitors/pharmacology ; Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/economics ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Aptamers, Nucleotide/therapeutic use ; Bevacizumab ; Capillary Permeability/drug effects ; Cholestanols/therapeutic use ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Double-Blind Method ; Drug Design ; Drugs, Investigational/pharmacology ; Eye Proteins/physiology ; Humans ; Injections ; Lactates/therapeutic use ; Macular Degeneration/physiopathology ; Models, Animal ; Multicenter Studies as Topic ; Nerve Growth Factors/physiology ; Pigment Epithelium of Eye/metabolism ; Pigment Epithelium of Eye/pathology ; Protein Isoforms/antagonists & inhibitors ; Protein Isoforms/physiology ; RNA Interference ; RNA, Small Interfering/pharmacology ; RNA, Small Interfering/therapeutic use ; Randomized Controlled Trials as Topic ; Serpins/physiology ; Stilbenes/therapeutic use ; Treatment Outcome ; Vascular Endothelial Growth Factor A/pharmacology ; Vascular Endothelial Growth Factor A/physiology ; Vascular Endothelial Growth Factor Receptor-2/drug effects ; Vascular Endothelial Growth Factor Receptor-2/physiology ; Vitreous Body |
| مستخلص: | Angiogenesis, the growth of new blood vessels from existing blood vessels, is responsible for vision loss in a variety of ophthalmic diseases. In neovascular age-related macular degeneration (AMD), the leading cause for legal blindness in many industrialised countries, abnormal blood vessels grow in the macula and cause blindness. There are a number of factors important in the angiogenic cascade but VEGF-A has been implicated in recent years as the major factor responsible for neovascular and exudative diseases of the eye. Numerous antiangiogenic drugs are in development but anti-VEGF drugs have shown great promise in treating neovascular AMD and other ocular diseases, and many of these drugs have been adopted from oncology where antiangiogenic therapy is gaining wide acceptance. For the first time in neovascular AMD, anti-VEGF drugs have brought the hope of vision improvement to a significant proportion of patients. This review provides an overview on angiogenic mechanisms, potential antiangiogenic treatment strategies and different antiangiogenic drugs with special focus on neovascular AMD. |
| Number of References: | 126 |
| المشرفين على المادة: | 0 (Angiogenesis Inhibitors) 0 (Antibodies, Monoclonal) 0 (Antibodies, Monoclonal, Humanized) 0 (Aptamers, Nucleotide) 0 (Cholestanols) 0 (Drugs, Investigational) 0 (Eye Proteins) 0 (Lactates) 0 (Nerve Growth Factors) 0 (Protein Isoforms) 0 (RNA, Small Interfering) 0 (Serpins) 0 (Stilbenes) 0 (Vascular Endothelial Growth Factor A) 0 (pigment epithelium-derived factor) 2H1PA8H1EN (pegaptanib) 2S9ZZM9Q9V (Bevacizumab) 4WE915J1KX (squalamine lactate) EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2) I5590ES2QZ (fosbretabulin) |
| تواريخ الأحداث: | Date Created: 20060622 Date Completed: 20060818 Latest Revision: 20220309 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1517/13543784.15.7.779 |
| PMID: | 16787141 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-7658 |
|---|---|
| DOI: | 10.1517/13543784.15.7.779 |